Wesley Buckingham

PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor–Positive Early Breast Cancer

Anne‐Vibeke Lænkholm, Maj‐Britt Jensen, Jens Ole Eriksen et al. · Journal of Clinical Oncology · 2018 · 188 citations

Medicine, Endocrinology, Oncology +17

Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay

Aleix Prat, Patricia Galván, Begoña Jiménez et al. · Clinical Cancer Research · 2015 · 97 citations

Medicine, Oncology, Pathology +17

The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer

Maj‐Britt Jensen, Anne‐Vibeke Lænkholm, Torsten O. Nielsen et al. · Breast Cancer Research · 2018 · 59 citations · Full text

Medicine, Oncology, Pharmacology +17

The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients

Maj‐Britt Jensen, Anne‐Vibeke Lænkholm, Eva Balslev et al. · npj Breast Cancer · 2020 · 28 citations · Full text

Medicine, Oncology, Pharmacology +15

Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer

Anne‐Vibeke Lænkholm, Maj‐Britt Jensen, Jens Ole Eriksen et al. · Clinical Breast Cancer · 2020 · 26 citations

Medicine, Gynecology, Oncology +14